The ROS1 mutation is a mutation occurring in the ROS1 oncogene on chromosome 6 resulting in a defective receptor tyrosine kinase which has structural similarity to the anaplastic lymphoma kinase (ALK) protein.
It is thought to be present in several cancers of the subtype non-small cell lung cancers (NSCLC) (1-2%).
Useful for assessing appropriateness of treatment agents such as crizotinib.
History and etymology
It is thought to have been first identified by Rikova et al 3.
- 1. Lin JJ, Shaw AT. Recent Advances in Targeting ROS1 in Lung Cancer. (2017) Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 12 (11): 1611-1625. doi:10.1016/j.jtho.2017.08.002 - Pubmed
- 2. Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. (2016) Virchows Archiv : an international journal of pathology. 469 (5): 489-503. doi:10.1007/s00428-016-2000-3 - Pubmed
- 3. Joshi A, Pande N, Noronha V, Patil V, Kumar R, Chougule A, Trivedi V, Janu A, Mahajan A, Prabhash K. ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes. (2019) Ecancermedicalscience. 13: 900. doi:10.3332/ecancer.2019.900 - Pubmed